FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc interim CEO Anthony Durkacz joined Proactive to discuss its agreement with Covar Pharmaceuticals Inc to start work on providing research quantities of its drug candidate, Lucid-PSYCH further clinical evaluation.
Durkacz says this the first step to advance its Lucid-PSYCH drug candidate through the drug development process, where it aims to treat major depressive disorders.